6 results on '"De Lorenzo D"'
Search Results
2. MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study
- Author
-
Ilaria Francaviglia, Paolo Lopedote, Filippo Gagliardi, Fabio Ciceri, Sara Steffanoni, Rita Daverio, Teresa Calimeri, Elena Anghileri, Maria Rosa Terreni, Marianna Sassone, Roberto Furlan, Piera Angelillo, Vittoria Tarantino, Maurilio Ponzoni, Chiara Iacona, Claudio Tripodo, Cristina Belloni, Alessandro Gulino, Daniela De Lorenzo, Massimo Filippi, Marica Eoli, Elena Guggiari, Maria Giulia Cangi, Vittorio Martinelli, Massimo Locatelli, Annamaria Finardi, Andrés J.M. Ferreri, Andrea Falini, Nicoletta Anzalone, Marco Foppoli, Alessandro Nonis, Pietro Mortini, Claudio Doglioni, Angelo Diffidenti, Ferreri, A. J. M., Calimeri, T., Lopedote, P., Francaviglia, I., Daverio, R., Iacona, C., Belloni, C., Steffanoni, S., Gulino, A., Anghileri, E., Diffidenti, A., Finardi, A., Gagliardi, F., Anzalone, N., Nonis, A., Furlan, R., De Lorenzo, D., Terreni, M. R., Martinelli, V., Sassone, M., Foppoli, M., Angelillo, P., Guggiari, E., Falini, A., Mortini, P., Filippi, M., Tarantino, V., Eoli, M., Ciceri, F., Doglioni, C., Tripodo, C., Locatelli, M., Cangi, M. G., Ponzoni, M., Ferreri A.J.M., Calimeri T., Lopedote P., Francaviglia I., Daverio R., Iacona C., Belloni C., Steffanoni S., Gulino A., Anghileri E., Diffidenti A., Finardi A., Gagliardi F., Anzalone N., Nonis A., Furlan R., De Lorenzo D., Terreni M.R., Martinelli V., Sassone M., Foppoli M., Angelillo P., Guggiari E., Falini A., Mortini P., Filippi M., Tarantino V., Eoli M., Ciceri F., Doglioni C., Tripodo C., Locatelli M., Cangi M.G., and Ponzoni M.
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Lymphoma ,Biopsy ,Concordance ,interleukin-10 ,diffuse large B-cell lymphoma ,Mutation, Missense ,Central Nervous System Neoplasms ,03 medical and health sciences ,primary CNS lymphoma ,0302 clinical medicine ,Cerebrospinal fluid ,hemic and lymphatic diseases ,Biomarkers, Tumor ,TaqMan ,medicine ,Humans ,diffuse large B-cell lymphoma, interleukin-10, interleukin-6, MYD88 L265P mutation, primary CNS lymphoma ,Prospective cohort study ,Aged ,medicine.diagnostic_test ,business.industry ,interleukin-6 ,Primary central nervous system lymphoma ,Hematology ,Middle Aged ,medicine.disease ,Interleukin-10 ,Neoplasm Proteins ,MYD88 L265P mutation ,Amino Acid Substitution ,030220 oncology & carcinogenesis ,Myeloid Differentiation Factor 88 ,Female ,business ,Diffuse large B-cell lymphoma ,030215 immunology - Abstract
Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n=36) and relapsed (n=27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reaction. IL-6 and IL-10 messenger RNA (mRNA) was assessed on PCNSL biopsies using RNAscope technology. IL levels in CSF were assessed by enzyme-linked immunosorbent assay. Mut-MYD88 was detected in 15/17 (88%) PCNSL biopsies, with an 82% concordance in paired tissue-CSF samples. IL-10 mRNA was detected in lymphomatous B cells in most PCNSL; expression of IL-6 transcripts was negligible. In CSF samples, mut-MYD88 and high IL-10 levels were detected, respectively, in 72% and 88% of patients with newly diagnosed PCNSL and in 1% of controls; conversely, IL-6 showed a low discriminating sensitivity and specificity. Combined analysis of MYD88 and IL-10 exhibits a sensitivity and specificity to distinguish PCNSL of 94% and 98% respectively. Similar figures were recorded in patients with relapsed PCNSL. In conclusion, high detection rates of mut-MYD88 and IL-10 in CSF reflect, respectively, the MYD88 mutational status and synthesis of this IL in PCNSL tissue. These biomarkers exhibit a very high sensitivity and specificity in detecting PCNSL both at initial diagnosis and relapse. Implications of these findings in patients with lesions unsuitable for biopsy deserve to be investigated.
- Published
- 2021
- Full Text
- View/download PDF
3. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation
- Author
-
Eloise Scarano, Vittoria Tarantino, Sara Steffanoni, Piera Angelillo, Chiara Rusconi, C. Cecchetti, Maurilio Ponzoni, Marco Foppoli, Alessandro Re, Caterina Stelitano, Alessandro Nonis, Salvatore Perrone, Michele Spina, Stefano Volpetti, Maurizio Frezzato, Marianna Sassone, Renato Zambello, Alice Di Rocco, Annalisa Arcari, Fabio Ciceri, Andrés J.M. Ferreri, Alberto Fabbri, Daniela De Lorenzo, Francesco Zaja, Teresa Calimeri, Giovanni Bertoldero, Ferreri, Ajm, Sassone, M, Angelillo, P, Zaja, F, Re, A, Di Rocco, A, Spina, M, Fabbri, A, Stelitano, C, Frezzato, M, Volpetti, S, Zambello, R, Rusconi, C, De Lorenzo, D, Scarano, E, Arcari, A, Bertoldero, G, Nonis, A, Calimeri, T, Perrone, S, Cecchetti, C, Tarantino, V, Steffanoni, S, Foppoli, M, Ciceri, F, Ponzoni, M., Ferreri, A. J. M., Sassone, M., Angelillo, P., Zaja, F., Re, A., Di Rocco, A., Spina, M., Fabbri, A., Stelitano, C., Frezzato, M., Volpetti, S., Zambello, R., Rusconi, C., De Lorenzo, D., Scarano, E., Arcari, A., Bertoldero, G., Nonis, A., Calimeri, T., Perrone, S., Cecchetti, C., Tarantino, V., Steffanoni, S., Foppoli, M., and Ciceri, F.
- Subjects
Male ,Oncology ,Cancer Research ,Lymphoma ,Salvage therapy ,Angiogenesis Inhibitors ,0302 clinical medicine ,Autologous stem-cell transplantation ,80 and over ,cell of origin ,diffuse large B-cell lymphoma ,immunomodulators ,lenalidomide ,maintenance ,transformed high-grade lymphoma ,Aged, 80 and over ,immunomodulator ,Hematology ,General Medicine ,Middle Aged ,Prognosis ,Diffuse ,Survival Rate ,Local ,030220 oncology & carcinogenesis ,Female ,Lymphoma, Large B-Cell, Diffuse ,medicine.drug ,Adult ,medicine.medical_specialty ,Neutropenia ,Maintenance Chemotherapy ,03 medical and health sciences ,Chemoimmunotherapy ,Internal medicine ,Large B-Cell ,medicine ,Humans ,Autologous transplantation ,Aged ,Follow-Up Studies ,Lenalidomide ,Neoplasm Recurrence, Local ,Salvage Therapy ,Survival rate ,business.industry ,medicine.disease ,Neoplasm Recurrence ,business ,Diffuse large B-cell lymphoma ,030215 immunology - Abstract
We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for 2 years or until progression or unacceptable toxicity. Primary endpoint was 1-year PFS. Forty-six of 48 enrolled patients were assessable. Most patients had IPI ≥2, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70 years. Lenalidomide was well tolerated. With the exception of neutropenia, grade-4 toxicities occurred in
- Published
- 2020
4. Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial
- Author
-
Letterio S. Politi, Daniela De Lorenzo, Andrés J.M. Ferreri, Eltjona Rrapaj, Claudio Bordignon, Vittoria Tarantino, Fabio Ciceri, Angelo Corti, Eloise Scarano, Nicoletta Anzalone, Paolo Lopedote, Gian Marco Conte, Piera Angelillo, Maurilio Ponzoni, Marianna Sassone, Teresa Calimeri, Flavio Curnis, Federico Fallanca, Marco Foppoli, Alessandro Nonis, Giovanni Citterio, Dario Cattaneo, Elena Guggiari, Sara Steffanoni, Ferreri, A. J. M., Calimeri, T., Ponzoni, M., Curnis, F., Conte, G. M., Scarano, E., Rrapaj, E., De Lorenzo, D., Cattaneo, D., Fallanca, F., Nonis, A., Foppoli, M., Lopedote, P., Citterio, G., Politi, L. S., Sassone, M., Angelillo, P., Guggiari, E., Steffanoni, S., Tarantino, V., Ciceri, F., Bordignon, C., Anzalone, N., and Corti, A.
- Subjects
Oncology ,Vincristine ,medicine.medical_specialty ,Clinical Trials and Observations ,medicine.medical_treatment ,Recombinant Fusion Proteins ,NGR-hTNF ,Internal medicine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Cyclophosphamide ,Lenalidomide ,Chemotherapy ,business.industry ,Tumor Necrosis Factor-alpha ,Standard treatment ,Primary central nervous system lymphoma ,Endothelial Cells ,Hematology ,medicine.disease ,Chemotherapy regimen ,Doxorubicin ,Prednisone ,Rituximab ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment of diffuse large B-cell lymphoma (DLBCL). Primary DLBCL of the central nervous system (CNS) (primary central nervous system lymphoma [PCNSL]) is an exception because of the low CNS bioavailability of related drugs. NGR–human tumor necrosis factor (NGR-hTNF) targets CD13+ vessels, enhances vascular permeability and CNS access of anticancer drugs, and provides the rationale for the treatment of PCNSL with R-CHOP. Herein, we report activity and safety of R-CHOP preceded by NGR-hTNF in patients with PCNSL relapsed/refractory to high-dose methotrexate-based chemotherapy enrolled in a phase 2 trial. Overall response rate (ORR) was the primary endpoint. A sample size of 28 patients was considered necessary to demonstrate improvement from 30% to 50% ORR. NGR-hTNF/R-CHOP would be declared active if ≥12 responses were recorded. Treatment was well tolerated; there were no cases of unexpected toxicities, dose reductions or interruptions. NGR-hTNF/R-CHOP was active, with confirmed tumor response in 21 patients (75%; 95% confidence interval, 59%-91%), which was complete in 11. Seventeen of the 21 patients with response to treatment received consolidation (ASCT, WBRT, and/or lenalidomide maintenance). At a median follow-up of 21 (range, 14-31) months, 5 patients remained relapse-free and 6 were alive. The activity of NGR-hTNF/R-CHOP is in line with the expression of CD13 in both pericytes and endothelial cells of tumor vessels. High plasma levels of chromogranin A, an NGR-hTNF inhibitor, were associated with proton pump inhibitor use and a lower remission rate, suggesting that these drugs should be avoided during TNF-based therapy. Further research on this innovative approach to CNS lymphomas is warranted. The trial was registered as EudraCT: 2014-001532-11.
- Published
- 2020
5. Development and verification of process concepts for the splitting of sulphuric acid by concentrated solar radiation
- Author
-
Roeb, Martin, Noglik, Adam, Monnerie, Nathalie, Schmitz, Mark, Sattler, Christian, Cerri, Giovanni, de Maria, Giovanni, Giovanelli, Ambra, Orden, Alfrdo, de Lorenzo, Daniel, Cedillio, J., le Digou, Alain, Borgard, Jean-Marc, Roeb, M, Noglik, A, Monnerie, N, Schmitz, M, Sattler, C, Cerri, G, DE MARIA, G, Giovannelli, Ambra, Orden, A, DE LORENZO, D, Cedillo, J, LE DUIGOU, A, and Borgard, J. M.
- Subjects
Thermochemical Cycles ,Hydrogen - Published
- 2006
6. HYTHEC: Development of a dedicated solar receiver-reactor for the decomposition of sulphuric acid
- Author
-
Roeb, Martin, Noglik, Adam, Rietbrock, Peter-Michael, Mohr, Stefan, de Oliveira, Lamark, Sattler, Christian, Cerri, Giovanni, de Maria, Giovanni, Giovanelli, Ambra, Buenaventura, Arturo, de Lorenzo, Daniel, Roeb, M, Noglik, A, RIETBROCK P., M, Mohr, S, DE OLIVEIRA, L, Sattler, C, Cerri, G, DE MARIA, G, Giovannelli, Ambra, Buenaventura, A, and DE LORENZO, D.
- Subjects
thermochemical cycles ,nuclear ,hydrogen ,sulfur iodine ,HYTHEC ,solar - Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.